A 58-year-old woman with a 10-year history of chronic pancreatitis (alcohol-related) presents with new-onset epigastric pain, anorexia, and weight loss of 5 kg over 1 month. CA 19-9 level is 240 U/mL (normal <37). MRI abdomen shows a 2.5 cm hypointense lesion in the pancreatic body with loss of the fat plane between the lesion and the splenic vessels. The patient has good performance status (ECOG 0) and no distant metastases on staging CT. What is the most appropriate treatment strategy?

Explanation

## Clinical Context: Pancreatic Cancer in Chronic Pancreatitis **Key Point:** Patients with chronic pancreatitis have a 40–50-fold increased risk of pancreatic cancer. New symptoms (pain, weight loss) or rising tumor markers in a chronic pancreatitis patient warrant aggressive investigation and treatment. **High-Yield:** Distal pancreatic cancers (body/tail) are often locally advanced at diagnosis because they present late. Neoadjuvant chemotherapy improves resection rates and overall survival in borderline-resectable disease. ## Why Neoadjuvant Chemotherapy Is Optimal This patient has: - **Borderline-resectable disease** (vascular involvement of splenic vessels without distant metastases) - **Good performance status** (ECOG 0) — candidate for aggressive multimodal therapy - **No metastases** — resection is potentially curative **Rationale for neoadjuvant approach:** 1. **Downstages the tumor** — chemotherapy may allow R0 resection 2. **Improves survival** — neoadjuvant + surgery > surgery alone in borderline-resectable disease 3. **Assesses chemosensitivity** — identifies patients who will benefit from adjuvant therapy 4. **Allows time for staging** — confirms no occult metastases before surgery **Clinical Pearl:** The ESPAC-4 trial and NCCN guidelines recommend neoadjuvant chemotherapy (gemcitabine + nab-paclitaxel or FOLFIRINOX) for borderline-resectable pancreatic cancer, followed by surgery if there is no progression. ## Comparison of Surgical Options | Procedure | Indication | Morbidity | |-----------|-----------|----------| | **Distal pancreatectomy + splenectomy** | Body/tail tumors without vascular involvement | Lower morbidity than Whipple | | **Whipple (PD)** | Head/uncinate tumors; ampullary cancers | Higher morbidity; not needed for body tumors | **Why distal pancreatectomy is correct:** The tumor is in the pancreatic body, not the head. Whipple's procedure is anatomically inappropriate and adds unnecessary morbidity. ## Why Other Options Are Incorrect **Mnemonic: NACT-THEN-RESECT** — Neoadjuvant chemotherapy before resection in borderline-resectable disease improves outcomes. | Option | Why Not Chosen | |--------|----------------| | **Upfront distal pancreatectomy** | Vascular involvement (splenic vessels) makes this borderline-resectable. Neoadjuvant chemotherapy should precede surgery to improve R0 resection rates and survival. | | **Whipple's procedure** | Anatomically incorrect — the tumor is in the pancreatic body, not the head. Whipple is for head/uncinate tumors and would add unnecessary morbidity without benefit. | | **Palliative chemotherapy alone** | The patient has no metastases and good performance status. Palliative approach is inappropriate; curative intent surgery after neoadjuvant therapy is the standard of care. | **Warning:** Do not confuse tumor location with surgical approach. Body/tail tumors require distal pancreatectomy, not Whipple's. Whipple is reserved for head/uncinate tumors.